[go: up one dir, main page]

WO1994012219A3 - Modified insulin-like growth factors - Google Patents

Modified insulin-like growth factors Download PDF

Info

Publication number
WO1994012219A3
WO1994012219A3 PCT/US1993/011458 US9311458W WO9412219A3 WO 1994012219 A3 WO1994012219 A3 WO 1994012219A3 US 9311458 W US9311458 W US 9311458W WO 9412219 A3 WO9412219 A3 WO 9412219A3
Authority
WO
WIPO (PCT)
Prior art keywords
igf
modified forms
growth factors
muteins
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1993/011458
Other languages
French (fr)
Other versions
WO1994012219A2 (en
Inventor
George N Cox
Martin J Mcdermott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Boulder Inc
Original Assignee
Synergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synergen Inc filed Critical Synergen Inc
Priority to JP6513381A priority Critical patent/JPH08506095A/en
Priority to EP94907044A priority patent/EP0679095A1/en
Priority to AU60482/94A priority patent/AU6048294A/en
Priority to KR1019950702108A priority patent/KR950703999A/en
Publication of WO1994012219A2 publication Critical patent/WO1994012219A2/en
Publication of WO1994012219A3 publication Critical patent/WO1994012219A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Modified forms of insulin-like growth factor (IGF) are provided which demonstrate improved pharmacological and biological properties. These modifications include IGF muteins produced by substituting or adding a cysteine in the amino acid sequence of native IGF as well as such muteins attached to polyethylene glycol (PEG) at the free cysteine site. The present invention further provides methods of making such modified forms. The IGF-PEG conjugates can be formulated into pharmaceutical compositions and used for the therapeutic treatment of IGF associated conditions.
PCT/US1993/011458 1992-11-25 1993-11-24 Modified insulin-like growth factors Ceased WO1994012219A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP6513381A JPH08506095A (en) 1992-11-25 1993-11-24 Modified insulin-like growth factor
EP94907044A EP0679095A1 (en) 1992-11-25 1993-11-24 Modified insulin-like growth factors
AU60482/94A AU6048294A (en) 1992-11-25 1993-11-24 Modified insulin-like growth factors
KR1019950702108A KR950703999A (en) 1992-11-25 1993-11-24 MODIFIED INSULIN-LIKE GROWTH FACTORS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98051992A 1992-11-25 1992-11-25
US07/980,519 1992-11-25

Publications (2)

Publication Number Publication Date
WO1994012219A2 WO1994012219A2 (en) 1994-06-09
WO1994012219A3 true WO1994012219A3 (en) 1994-07-21

Family

ID=25527621

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/011458 Ceased WO1994012219A2 (en) 1992-11-25 1993-11-24 Modified insulin-like growth factors

Country Status (6)

Country Link
EP (1) EP0679095A1 (en)
JP (1) JPH08506095A (en)
KR (1) KR950703999A (en)
AU (1) AU6048294A (en)
CA (1) CA2149048A1 (en)
WO (1) WO1994012219A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859497B2 (en) 1997-07-14 2014-10-14 Bolder Biotechnology, Inc. Method of treatment using cysteine mutants of beta interferon
US8957023B2 (en) 1999-01-14 2015-02-17 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
EP0756494A1 (en) * 1994-05-24 1997-02-05 Amgen Boulder Inc. Modified insulin-like growth factors
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6870033B1 (en) 1997-02-21 2005-03-22 Genentech, Inc. Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
US7270809B2 (en) 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
EP1012184B1 (en) 1997-07-14 2007-10-10 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
WO2000042175A1 (en) 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US7005504B2 (en) 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
EP1067959A2 (en) 1998-04-03 2001-01-17 Chiron Corporation Use of igf1 for treating articular cartilage disorders
WO2000059926A1 (en) 1999-04-02 2000-10-12 Ajinomoto Co., Inc. Process for producing subunit peptide origintaing in polymer protein
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
NZ522847A (en) 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
EP2348043A1 (en) 2001-10-02 2011-07-27 Genentech, Inc. APO-2 ligand variants and uses thereof
US20060141561A1 (en) 2002-06-24 2006-06-29 Kelley Robert F Apo-2 ligand/trail variants and uses thereof
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
EP1674113A1 (en) * 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
WO2006134173A2 (en) * 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
US8329866B2 (en) 2005-10-03 2012-12-11 Bolder Biotechnology, Inc. Long acting VEGF inhibitors and methods of use
KR101106795B1 (en) 2006-08-31 2012-01-18 에프. 호프만-라 로슈 아게 Method for the production of insulin-like growth factor-i
CL2007002502A1 (en) 2006-08-31 2008-05-30 Hoffmann La Roche VARIANTS OF THE SIMILAR GROWTH FACTOR TO HUMAN INSULIN-1 (IGF-1) PEGILATED IN LISIN; METHOD OF PRODUCTION; FUSION PROTEIN THAT UNDERSTANDS IT; AND ITS USE TO TREAT ALZHEIMER'S DISEASE.
EP2091968A2 (en) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21 variants
US8617531B2 (en) 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
KR101485646B1 (en) * 2010-02-11 2015-01-22 에프. 호프만-라 로슈 아게 IGF-I poly (ethylene glycol) conjugate
CR20160132A (en) 2013-08-12 2016-08-25 Genentech Inc COMPOSITIONS AND METHOD TO TREAT CONDITIONS ASSOCIATED WITH THE COMPLEMENT
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
CN120757643A (en) 2020-03-24 2025-10-10 基因泰克公司 TIE2 binders and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0458064A2 (en) * 1990-05-04 1991-11-27 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
EP0458064A2 (en) * 1990-05-04 1991-11-27 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; *
GLASS J D ET AL: "4-PHENOXY-3,5-DINITROBENZOYL POLYETHYLENE GLYCOL REVERSIBLE ATTACHMENT OF CYSTEINE CONTAINING POLYPEPTIDES TO POLYMERS IN AQUEOUS SOLUTIONS.", BIOPOLYMERS, vol. 18, no. 2, 1979, pages 383 - 392 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859497B2 (en) 1997-07-14 2014-10-14 Bolder Biotechnology, Inc. Method of treatment using cysteine mutants of beta interferon
US8957023B2 (en) 1999-01-14 2015-02-17 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues

Also Published As

Publication number Publication date
CA2149048A1 (en) 1994-06-09
JPH08506095A (en) 1996-07-02
AU6048294A (en) 1994-06-22
KR950703999A (en) 1995-11-17
EP0679095A1 (en) 1995-11-02
WO1994012219A2 (en) 1994-06-09

Similar Documents

Publication Publication Date Title
WO1994012219A3 (en) Modified insulin-like growth factors
IE882442L (en) Administration of implants
IL104325A (en) Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
MY125556A (en) Aqueous formulations of peptide
KR970706842A (en) Acylated Insulin Analogs
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
GEP20022788B (en) Pharmaceutical Compositions Having Appetite Suppressant Activity
DE60012557D1 (en) COMPOSITIONS CONTAINING HYALURONIC ACID FOR THE DELIVERY OF OSTEOGENIC PROTEINS
AU3435497A (en) Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies
UA42747C2 (en) PEPTIDE DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD FOR STIMULATING GROWTH HORMONE SECRETION
EP1025840A3 (en) Oral drug compositions and methods
ATE79763T1 (en) USE OF AT LEAST ONE CYTOKINE IN THE MANUFACTURE OF A MEDICATION FOR THE SYSTEMIC TREATMENT OF PRAENEOPLASTIC LESIONS.
EP1234586A3 (en) Hepatoselective pharmaceutical actives
ATE399567T1 (en) PEG CONJUGATES OF LHRH ANALOGUE
MY135057A (en) Dolastatin 15 derivatives
WO2002055532A3 (en) Variant growth hormone molecules conjugated with macromolecular compounds
IL104580A0 (en) Parathormone fragments,process for the preparation thereof and pharmaceutical compositions containing them
AR019066A1 (en) HELIOMYCIN, NUCLEIC ACID FRAGMENTS CODING FOR HELIOMYCIN AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
EP0286441A3 (en) Novel cytotoxic protein
WO2002058589A3 (en) Agents and methods for promoting bone growth
WO2002081507A3 (en) Interferon gamma polypeptide variants
HUP9802197A2 (en) Novel peptides for use in treatment of t-cell mediated cartilage destruction in autoimmune diseases
DE69816808D1 (en) SOMATOSTATIN AGONISTE FOR REDUCING BODY WEIGHT
WO1994016723A3 (en) Wound healing composition
HRP20090571T1 (en) A PHARMACEUTICAL PREPARATION CONTAINING CYCLIC SOMATO STATIN ANALOGS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
EX32 Extension under rule 32 effected after completion of technical preparation for international publication
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
WWE Wipo information: entry into national phase

Ref document number: 2149048

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994907044

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1994907044

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1995 448514

Country of ref document: US

Date of ref document: 19951204

Kind code of ref document: A

EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Free format text: AM+,KG+,MD+,TJ+,TM+

LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)

Free format text: AM*,KG*,MD*,TJ*,TM*

WWW Wipo information: withdrawn in national office

Ref document number: 1994907044

Country of ref document: EP